On October 2, 2026 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, reported that two posters highlighting research on botensilimab (BOT), an Fc-enhanced multifunctional anti-CTLA-4 antibody, in combination with balstilimab (BAL), an anti-PD-1 antibody, have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting, taking place November 4-8, 2026, in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The clinical poster will review the features of long-term survivors of refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC) who have been treated with BOT+BAL. A second poster will highlight translational research of BOT+BAL in combination with MiNK Therapeutics’ agenT-797 (iNKT cell therapy) with in a preclinical model of colorectal cancer liver metastases.

Presentation Details

Abstract Title: Clinical features of long-term survivors treated with next-generation anti-CTLA-4 (botensilimab) plus anti-PD-1 (balstilimab) in refractory microsatellite-stable metastatic colorectal cancer
Presenter: Thomas U. Marron, MD, PhD; Mount Sinai, Tisch Cancer Center, New York, NY, USA
Date: Saturday, November 7, 2026
Time: 10:00 a.m. – 2:00 p.m. and 6:00-8:10 p.m. MST
Location: North Building, Lower Level, Exhibition Halls 4–5–6
Poster No.: 472

Abstract Title: AgenT-797, an allogeneic iNKT cell therapy, enables tumor-cell killing in a human organoid model of immune checkpoint inhibitor–refractory colorectal cancer liver metastases
Presenter: Shanmugarajan Krishnan, Ph.D., M.S., B.S.; Agenus Inc., Lexington, MA
Date: Saturday, November 7, 2026
Time: 10:00 a.m. to 2:00 p.m. and 6:00 to 8:10 p.m. MST
Location: North Building, Lower Level, Exhibition Halls 4–5–6
Poster No.: 270

(Press release, Agenus, OCT 2, 2026, View Source [SID1234671243])

On October 2, 2026 Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, reported that a poster will be presented at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), taking place November 4-8, 2026, in Phoenix, AZ, demonstrating that atebimetinib enhances PD-1 checkpoint blockade in RAS mutant tumor models. These findings support Immuneering’s plans to conduct a Phase 2 study of atebimetinib in combination with PD-1 blockade in patients with lung cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Poster Presentation Details:
Title: Cyclic disruption of the mitogen-activated protein kinase (MAPK) pathway by the pulsatile MEK inhibitor, Atebimetinib, enhances PD-1 checkpoint blockade in RAS mutant tumors.
Lead author: Amy E. Axel, Immuneering
Abstract Number: 377
Date and Time: Friday, November 6, 2026, 10:00 a.m. MT

Following presentation, the poster will be available on the publications section of Immuneering’s website at View Source

(Press release, Immuneering, OCT 2, 2026, View Source [SID1234671242])

On October 2, 2026 Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapies for oncology and inflammation and immunology (I&I), reported that interim results from the STARt-002 clinical study have been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 41st Annual Meeting, taking place November 4–8, 2026, in Phoenix, Arizona.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Invikafusp alfa is designed for antigen-rich tumors. ADCs like TRODELVY help create that state by releasing tumor antigens and inflaming the tumor microenvironment, priming less immunogenic tumors for T-cell-mediated responses," said Kevin Chin, M.D., Chief Medical Officer of Marengo Therapeutics. "STARt-002 is the first clinical study to test this hypothesis by pairing a selective T-cell agonist with an ADC, and this combination could extend invikafusp alfa’s reach beyond tumors that are antigen-rich on their own. Triple-negative and HRpositive/HER2-negative metastatic breast cancer are two settings where patients still have limited options after standard therapies. We look forward to presenting interim results from both cohorts at SITC (Free SITC Whitepaper)."

STARt-002 is the company’s Phase 1b/2 trial evaluating invikafusp alfa in combination with TRODELVY (sacituzumab govitecan-hziy) in patients with metastatic breast cancer. The Phase 2 portion is evaluating two distinct patient populations: metastatic triple-negative breast cancer (TNBC) and HR-positive/HER2-negative metastatic breast cancer. Following completion of the safety lead-in, both expansion cohorts are enrolling at the recommended Phase 2 dose at select cancer centers across North America. The SITC (Free SITC Whitepaper) presentation will feature interim results from both expansion cohorts, and Marengo expects to report additional data in 2027.

The STARt-002 combination strategy reflects invikafusp alfa’s long-term potential as an immuno-oncology backbone and builds on STARt-001, a Phase 1/2 trial evaluating invikafusp alfa monotherapy in patients with PD-1-resistant, biomarker-enriched solid tumors, including TNBC. Updated STARt-001 results will be presented during an oral presentation at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2026 Congress, taking place October 23–27 in Madrid, Spain.

Presentation Details
● Title: Initial clinical results from START-002: A Phase 1b/2 study of invikafusp alfa, a first-in-class dual T-cell agonist, in combination with sacituzumab govitecan in triplenegative or HR+/HER2- mBC
● Abstract Number: 514
● Session: Oral Abstract Session 3
● Date/Time: Saturday, November 7, 2026 3:30PM MT
● Presenter: Steven Isakoff, MD, PhD, MMSc; Mass General Brigham

(Press release, Marengo Therapeutics, OCT 2, 2026, View Source [SID1234671241])

On October 2, 2026 Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology platform, reported it will present new immune data for AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting, taking place in Phoenix, Arizona, November 4-8, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new data will reflect the systemic immunomodulatory effects of EVX-01 plus pembrolizumab beyond vaccine-specific T-cell responses using comprehensive immune profiling. It will be presented both in an oral and poster presentation at the SITC (Free SITC Whitepaper) meeting.

The new immune data stems from the phase 2 trial investigating EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with advanced melanoma. Each patient enrolled in the trial received a unique vaccine designed and manufactured based on their individual biology. KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

The complete three-year clinical data from the phase 2 trial will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2026 congress on October 24, 2026. Two-year data demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. Additionally, a durable clinical benefit was observed as 92% of patients were still responding at two years follow-up and no relapses were observed.

In the third year, patients received EVX-01 as stand-alone therapy, meaning the data will offer insight into the vaccine’s effect also when not administered in combination with anti-PD-1 therapy. Further, the data may also provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response.

SITC oral and poster presentation details:

Abstract title: EVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanoma
Abstract#: 502
Oral presentation:

Session: 105b: Rapid Oral – Clinical 1
Location: Phoenix Convention Center, West Building-300 Level – 301BC
Date/Time: Friday, November 6, 2026, 12:30-1:30pm MT / 20:30-21:30 CET
Presenter: Mads Lausen, Senior Scientist at Evaxion
Poster presentation:

Session: Poster Session
Location: Phoenix Convention Center, North Building -Lower Level – Exhibition Halls 4-6
Date/Time: Saturday, November 7, 2026, 12:30–1:30pm & 6:40–8:10pm MT / 20:30–21:30 CET & 02:40–04:10 CET (Sunday, November 8)
Presenter: Mads Lausen, Senior Scientist at Evaxion
About EVX-01
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors. It is currently being evaluated as a treatment of advanced melanoma and is Evaxion’s lead clinical asset.

Designed with our AI-Immunology platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system to fight off cancer by mounting a targeted response against tumor-specific neoantigens.

In the phase 2 trial in patients with advanced melanoma (skin cancer), EVX-01 has demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. 86% of the EVX-01 neoantigen targets triggered a tumor-specific immune response in the patients.

(Press release, Evaxion, OCT 2, 2026, View Source [SID1234671240])

On October 2, 2026 Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), reported that two presentations of new data from its ongoing Phase 1/2 study of imneskibart will be featured at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

One presentation will focus on promising Phase 2 results for imneskibart with avelumab in checkpoint inhibitor (CPI)-refractory adenocarcinoma non-small cell lung cancer (NSCLC). The second presentation will feature encouraging Phase 1/2 data for imneskibart with and without nivolumab in doublet CPI-refractory cutaneous melanoma. The SITC (Free SITC Whitepaper) Annual Meeting is being held virtually and in Phoenix, Arizona, from November 4-8, 2026.

Details of the poster presentations are as follows:

Title: Imneskibart, a human monoclonal antibody (mAb), + low-dose subcutaneous IL-2 + avelumab: Phase 2 promising activity in CPI-refractory adenocarcinoma non-small cell lung cancer (NSCLC)
Abstract: 605
Date and Time: Friday, November 6, 2026, 10:00 a.m.-2:00 p.m. and 5:00 p.m.-7:00 p.m. MST

Title: Imneskibart + low-dose subcutaneous IL-2 ± nivolumab in doublet checkpoint inhibitor-refractory melanoma: promising activity in an ongoing Phase 1/2 study
Abstract: 611
Date and Time: Friday, November 6, 2026, 10:00 a.m.-2:00 p.m. and 5:00 p.m.-7:00 p.m. MST

The posters will be presented in the Poster Hall (Exhibit Halls AB) at the Phoenix Convention Center. Electronic versions will also be available on the SITC (Free SITC Whitepaper) 2026 virtual meeting platform.

About Imneskibart
Imneskibart (AU-007) is a human IgG1 monoclonal antibody designed by leveraging artificial intelligence that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, imneskibart redirects IL-2 to reinforce anti-tumor immune effects. This is achieved by preventing IL-2, either exogenous or secreted by effector T cells, from binding to trimeric receptors on regulatory T cells while still allowing IL-2 to bind and expand effector T cells and NK cells. This prevents the negative feedback loop caused by other IL-2-based treatments and biases the immune system toward activation over suppression. Imneskibart also prevents IL-2 from binding to CD25-containing receptors on eosinophils, as well as vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.

To learn more about the imneskibart Phase 1/2 clinical trial program, including study locations in the United States and Australia, please visit ClinicalTrials.gov (identifier: NCT05267626), www.solidtumorstudy.com (U.S.) and www.solidtumourstudy.com (Australia).

(Press release, Aulos Bioscience, OCT 2, 2026, View Source [SID1234671239])